PECAM-1 GENE Polymorphisms and Soluble PECAM-1 LEVEL in Rheumatoid Arthritis and Systemic LUPUS Erythematosus Patients Is There a Link with Clinical Atherosclerotic Events? - ACR Meeting Abstracts

Abstract Number: 79

PECAM-1 GENE Polymorphisms and Soluble PECAM-1 LEVEL in Rheumatoid Arthritis and Systemic LUPUS Erythematosus Patients Is There a Link with Clinical Atherosclerotic Events?

Omer Nuri Pamuk¹, Hilmi Tozkir², Mehmet Sevki Uyanik³, Hakan Gurkan⁴, Julide Duymaz⁴, Salim Donmez⁵, Metin Yazar² and Gulsum Pamuk³, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Genetics, Trakya University Medical Faculty, EDIRNE, Turkey, ³Hematology, Trakya University Medical Faculty, Edirne, Turkey, ⁴Trakya University Medical Faculty, EDIRNE, Turkey, ⁵Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)

Session Information

Title: Genetics, Genomics and Proteomics I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31) which plays a role in the transmigration of leucocytes into tissues is a member of the immunoglobulin (Ig) superfamily. It was reported that the expression of PECAM-1 on synovial tissue in inflammatory arthritis is enhanced. The genetic polymorphisms of PECAM-1 were found to play roles in atherosclerotic events. We determined PECAM-1 polymorphisms, soluble PECAM-1 and CD40L levels in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE); and evaluated their associations with clinical atherosclerotic complications.

Methods: We included 100 RA and 81 SLE patients and 94 healthy controls into the study. The clinical features about patients were obtained from medical records. Past cardiovascular complications were recorded. The most frequent gene polymorphisms of PECAM-1 were studied in our genetics laboratory. Soluble PECAM-1 and CD40L levels in serum were determined with ELISA.

Results:

The frequencies of 373C (rs668) and 1688A (rs12953) alleles were higher in RA patients when compared to controls (p values, 0.03 and 0.023). RA and SLE patients had significantly higher allele frequencies for 2008A (rs1131012) when compared to controls (p values, 0.021 and 0.001). SLE patients had significantly more frequent AA genotype for rs1131012 polymorphism than RA patients and controls (p values, 0.007 and <0.001). Soluble PECAM-1 level was significantly higher in RA patients than in SLE patients and healthy controls (p values <0.001). The sCD40L level was also significantly higher in RA group than in SLE and control groups (p values, 0.006 and 0.047). The levels of sPECAM-1 and sCD40L were significantly higher in RA patients with AA genotype (rs1131012) than in patients with AG genotype (p values, 0.046 and 0.008). Atherosclerotic complications were more frequent in SLE patients with AG genotype (rs12953) than those with AA genotype (p=0.021). SLE patients with CC genotype (rs668) had a significantly lower frequency of atherosclerotic complications than those with CG genotype (p=0.045).

Conclusion: We found associations between various PECAM-1 polymorphisms and RA, SLE; PECAM-1 and sCD40L levels were significantly higher in RA patients than in SLE and control groups. Soluble PECAM-1 level in RA was found to be linked to a certain genotype; PECAM-1 polymorphisms in SLE were protective against atherosclerotic complications.

Disclosure:

O. N. Pamuk,
None;

H. Tozkir,
None;

M. S. Uyanik,
None;

H. Gurkan,
None;

J. Duymaz,
None;

S. Donmez,
None;

M. Yazar,
None;

G. Pamuk,
None.

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pecam-1-gene-polymorphisms-and-soluble-pecam-1-level-in-rheumatoid-arthritis-and-systemic-lupus-erythematosus-patients-is-there-a-link-with-clinical-atherosclerotic-events/

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].